High-intensity focused ultrasound (HIFU) developer SonaCare Medical has received U.S. Food and Drug Administration (FDA) clearance to market its Sonablate 450 system for the ablation of prostate tissue.
The firm said it expects to begin distributing the system in the U.S. in October. SonaCare previously received FDA clearance for its Sonatherm laparoscopic HIFU ablation device.